Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dorota Rytwinski

Psychiatry Fremont, OH Medical Doctor

NPI 1003960428 CMS profile 272551

715 S Taft Ave, Center For Mental Health And Well-Being, Fremont, OH 43420

Open in the dashboard

General payments

$10,261

623 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dorota Rytwinski of Fremont, OH is reported in the CMS Open Payments database as having received $10,261 across 623 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,491 149
2024 General $2,316 126
2023 General $2,021 114
2022 General $932 56
2021 General $561 38
2020 General $675 40
2019 General $1,265 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dorota Rytwinski
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Dorota Rytwinski were reported at $2,491. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Dorota Rytwinski Psychiatry median Middle half National median
2019 $1,265 $184 $59–$605 $163
2020 $675 $119 $36–$372 $114
2021 $561 $143 $43–$576 $132
2022 $932 $153 $50–$590 $149
2023 $2,021 $170 $56–$651 $160
2024 $2,316 $179 $57–$673 $164
2025 $2,491 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $1,639 90 payments
  2. Otsuka America Pharmaceutical, Inc. $1,211 98 payments
  3. AbbVie, Inc. $925 48 payments
  4. Teva Pharmaceuticals USA, Inc. $853 48 payments
  5. Lundbeck LLC $748 56 payments
  6. ITI, Inc. $587 42 payments
  7. Sunovion Pharmaceuticals Inc. $582 51 payments
  8. Janssen Pharmaceuticals, Inc $487 29 payments
  9. Neurocrine Biosciences, Inc. $484 25 payments
  10. Supernus Pharmaceuticals, Inc. $445 14 payments
  11. Other $2,301 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,022 619 payments
  2. Education $239 4 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $1,392 75 payments
  2. ARISTADA Cns $1,392 75 payments
  3. ARISTADA Cns $1,224 65 payments
  4. ARISTADA Cns $1,224 65 payments
  5. LYBALVI $921 54 payments
  6. ARISTADA INITIO $706 33 payments
  7. REXULTI Psychiatry $693 65 payments
  8. VRAYLAR $675 31 payments
  9. REXULTI Psychiatry $645 48 payments
  10. LATUDA $582 51 payments
  11. Other $7,166 420 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

7,513

Median for Psychiatry: 574

Drug cost

$1,725,983

Median for Psychiatry: $27,624

Branded share of claims

23.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 79 $258,755
Invega Trinza Paliperidone Palmitate Brand 24 $206,012
Austedo Xr Deutetrabenazine Brand 22 $199,963
Austedo Deutetrabenazine Brand 13 $181,370
Aplenzin Bupropion Hbr Brand 20 $98,349
Ingrezza Valbenazine Tosylate Brand 11 $92,385
Trintellix Vortioxetine Hydrobromide Brand 165 $86,599
Vraylar Cariprazine Hcl Brand 56 $77,487
Rexulti Brexpiprazole Brand 53 $71,581
Abilify Maintena Aripiprazole Brand 19 $54,959

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$23,053

Medicare's payments for the services billed

Medicare patients

89

Average age 58

Services billed

316

52 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 53%
Diabetes 34%
Arthritis 30%
COPD 20%
Chronic kidney disease 17%
Heart failure 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$298 56 —
REXULTI
$238 53 —
Auvelity
$226 — —
Qelbree
$199 — —
CAPLYTA
$175 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

623 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record